Irreversible Leukoencephalopathy in a Chinese Renal Transplant Recipient  by Cheung, Chi Yuen et al.
Hong Kong J Nephrol • October 2010 • Vol 12 • No 2 77
Case Report
INTRODUCTION
Tacrolimus and cyclosporine are currently widely used 
as primary immunosuppressive agents in organ transplant 
recipients. They are both calcineurin inhibitors and 
neurotoxicity is a significant complication attributable 
to the use of these agents. In most cases, the clinical 
picture can be completely reversed after discontinuation 
or dose reduction of calcineurin inhibitors. We herein 
report the case of a 52-year-old male who developed 
irreversible leukoencephalopathy 4 months after renal 
transplantation despite early withdrawal of tacrolimus.
CASE REPORT
A 52-year-old man with polycystic kidney disease under-
went deceased-donor renal transplantation. The immuno-
suppressive regimen included tacrolimus, mycophenolate 
mofetil (MMF) and prednisolone. His renal function 
was stable with serum creatinine around 110 μmol/L. 
One month later, he was hospitalized for progressive men-
tal dullness, but no seizure was observed. There was no 
fever, chills or rigor. Neurological examination revealed 
no meningism and no focal neurological signs.
Laboratory findings, including complete blood 
count, electrolytes (serum sodium, potassium, calcium 
and magnesium), thyroid function, and liver and renal 
function tests were all normal. Random blood glucose 
was 5.7 mmol/L. Total cholesterol level was 4.9 mmol/L. 
Erythrocyte sedimentation rate was 2 mm/hr and 
C-reactive protein was < 3.2 mg/L.
In view of confusion, cerebral computed tomography 
(CT) was arranged and showed bilateral small hy-
podense areas in the basal ganglia, compatible with 
an old insult (Figure 1A). Lumbar puncture was then 
performed and the cerebrospinal fluid (CSF) was clear. 
Ceftriaxone, acyclovir and antituberculosis therapy 
were empirically started immediately after lumbar 
puncture.
Preliminary CSF results revealed elevated protein level 
(1.18 g/L) but normal cell count and glucose level (Table). 
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Subsequent microbiological studies of CSF showed 
no indication of bacterial, fungal or Mycobacterium 
tuberculosis infection. Polymerase chain reaction 
analyses for the herpes virus and polyomavirus (includ-
ing JC virus) in CSF were also negative (Table). There-
fore, both acyclovir and antituberculosis therapy were 
stopped. Other sepsis work-up, including serum cyto-
megalovirus pp65 antigen, was found to be negative.
Before the onset of symptoms, he was on predniso-
lone 7.5 mg daily, MMF 1,250 mg daily, and tacrolimus 
4 mg daily (0.05 mg/kg/day). Limited sampling strategy 
and abbreviated AUC0–12 was used for tacrolimus 
monitoring and drug titration in our center [1]. The ab-
breviated tacrolimus AUC0–12 was 160 ng × hr/mL (target 
range, 80–100 ng × hr/mL). The dosage of tacrolimus 
was reduced. MMF was stopped and prednisolone was 
replaced by intravenous hydrocortisone immediately 
after hospitalization.
The patient’s mental state deteriorated rapidly after 
hospitalization and he required intubation and mechan-
ical ventilation support. Electroencephalography did 
not reveal any epileptiform activity. Cerebral magnetic 
resonance imaging showed diffuse subtle T2 intense 
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Figure 1. Serial cerebral computed tomography scans show progressive leukoencephalopathy: (A) during onset of symptoms; (B) at 1 month; 
(C) at 2 months; and (D) at 3 months.
Table. Biochemical and microbiological findings of cerebrospinal 
fluid
Appearance Clear
Total protein 1.18 g/L
Glucose 5.3 mmol/L (blood glucose, 
  10.1 mmol/L)
White blood cells 8/mm3
Gram smear  Negative
Bacterial culture No growth
AFB smear and culture Negative
Mycobacterium tuberculosis DNA Negative
Indian ink stain No capsulated yeast cells
Cryptococcal antigen Negative
Fungal culture Negative
PCR herpes virus Negative
PCR polyomavirus Negative
Cytology No malignant cells
AFB = acid-fast bacilli; PCR = polymerase chain reaction.
signal changes in periventricular deep white matter 
(Figure 2), but there was no leptomeningeal or other 
parenchymal contrast enhancement. Brain biopsy was 
planned but refused by the patient’s relatives. Repeated 
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abbreviated tacrolimus AUC0–12 was 100 ng × hr/mL. 
Tacrolimus was subsequently replaced by sirolimus 
1 week after hospitalization in view of poor neurologi-
cal recovery despite tacrolimus dose reduction. How-
ever, the patient’s neurological condition progressively 
worsened, resulting in a comatose state. Cerebral CT 
was repeated 4 weeks later, which showed evidence of 
generalized cerebral edema extending from bilateral 
corona radiata, through thalami to brainstem (Figure 
1B). Serial cerebral CT showed progressive deteriora-
tion with extensive white matter hypodensity, compat-
ible with severe and diffuse leukoencephalopathy 
(Figure 1C). There was no improvement in his mental 
state. Cerebral CT taken 3 months after hospitalization 
showed extensive brain parenchymal volume loss, indi-
cating irreversible cerebral damage (Figure 1D). During 
the entire clinical course, there was no evidence of graft 
dysfunction. The patient remained comatose and sub-
sequently died of fulminant pneumonia 5 months after 
hospitalization.
DISCUSSION
Immunosuppressive agent-associated leukoencepha-
lopathy is a rare complication after solid organ transplan-
tation. It has been included within the reversible posterior 
leukoencephalopathy syndrome, which consists of revers-
ible vasogenic edema in posterior circulation territories, 
although conversion to irreversible cytotoxic edema has 
been described [2]. The exact mechanism for tacrolimus-
associated cerebral neurotoxicity is unknown.
Neurotoxicity may occur at therapeutic levels of 
tacrolimus and, thus, serum drug levels may not be 
reliable diagnostic markers of severe neurotoxicity in-
duced by tacrolimus [3]. Slightly elevated CSF protein 
level, as in our patient, was observed in 25% of the 
published cases [4]. Brain magnetic resonance imaging 
is the most sensitive diagnostic study of leukoencepha-
lopathy and should be arranged early if it is clinically 
suspicious. Occipital, parietal and temporal lobes are the 
most common sites of neuroimaging abnormalities, 
although other areas may also be involved. Neuroimaging 
abnormalities are usually located in the subcortical white 
matter but may extend into the deeper white matter or 
the cortical ribbon [4]. The site of the neuroimaging 
abnormalities in our patient was atypical. Contrary to the 
classical posterior white matter involvement, the initial 
CT scan abnormalities in our patient involved hypoden-
sities over bilateral corona radiata, the thalami and the 
brainstem. On the other hand, typical neuroimaging 
features such as symmetrical distribution and the non-
enhancing nature of the lesions were present in our patient 
[3]. This symmetrical involvement, together with exten-
sive cerebral edema in the later stage, are typical of drug 
toxic effect.
There is no specific treatment for this condition. In 
most cases, reduction or cessation of tacrolimus can 
reverse the neurotoxicity. Significant improvement or 
complete resolution of the clinical signs and symptoms 
occurs within days, with resolution of neuroimaging 
abnormalities usually lagging behind [4]. In rare cases, 
however, progression to ischemia and massive infarction 
will result in significant mortality and morbidity [3]. 
Serial neuroimaging in our patient revealed progression 
to generalized cerebral white matter edema within 2 
months, even after early withdrawal of tacrolimus. The 
cerebral edema finally subsided but there was extensive 
cerebral atrophy, which could explain the fatal and 
catastrophic course of disease in our patient.
An important differential diagnosis in our patient 
was progressive multifocal leukoencephalopathy 
(PML). The median time to disease onset is 30 months 
after transplantation in renal transplant recipients [5]. 
In our patient, the onset of symptoms was only 4 months, 
which might be too early for the development of PML. 
Moreover, our patient initially presented with progres-
sive mental dullness without any focal neurological 
deficits. This can be explained by diffuse cerebral in-
volvement, rendering the diagnosis of drug toxicity more 
likely. Furthermore, the absence of clinical and labora-
tory evidence of infection make the diagnosis of PML 
less likely. Polymerase chain reaction of CSF for JC 
virus is now accepted as a diagnostic test for PML [6]. 
It was negative in our patient, but a negative result does 
not rule out PML. Brain biopsy remains the most reliable 
and accurate method for diagnosing JC virus-associated 
PML [5].
In conclusion, leukoencephalopathy can be a serious 
complication of tacrolimus use. Our report of such 
non-posterior and irreversible leukoencephalopathy 
after tacrolimus therapy for renal transplantation is 
important. It should alert clinicians to consider early 
Figure 2. Cerebral magnetic resonance imaging shows diffuse subtle 
T2 intense signal changes in periventricular deep white matter.
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withdrawal of tacrolimus when tacrolimus-related 
leukoencephalopathy is suspected.
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